pocketful logo light
pocketful logo light
Emmessar Biotech & Nutrition Ltd logo

Emmessar Biotech & Nutrition Ltd

NSE: BSE: 524768

26

(2.36%)

Mon, 25 May 2026, 10:05 am

Emmessar Biotech & Nutrition Share Price Live Chart

1 Day

(2.36%)

No Result Found

Summary

  • Market Cap

    12.37

  • Net Profit

    0.32

  • P/B

    1.97

  • Sector P/E

    43.43

  • P/E

    48.24

  • EV/EBITDA

    7.85

  • Debt/Equity (Industry)

    0.36

  • Interest Cover (Industry)

    4.90

  • ROCE (Industry)

    9.74

  • RONW (Industry)

    7.99

  • ROE

    4.23

  • ROCE

    11.52

  • Debt/Equity

    0.01

  • EPS (TTM)

    0.87

  • Dividend Yield

    0

  • Book Value

    16.24

  • Interest Cover

    0

Analysis

all

thumbs up icon

Pros

  • Emmessar Biotech & Nutrition is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
  • Emmessar Biotech & Nutrition is profitable, therefore cash runway is not a concern.
  • Emmessar Biotech & Nutrition has no debt, it does not need to be covered by operating cash flow.
  • Emmessar Biotech & Nutrition has no debt, it does not need to be covered by short term assets.
thumbs up icon

Cons

  • Unable to evaluate Emmessar Biotech & Nutrition's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Emmessar Biotech & Nutrition's dividend against the top 25% market benchmark as the company has not reported any payouts.
  • High level of physical assets or inventory.
  • Emmessar Biotech & Nutrition is not covered by any analysts.
  • Emmessar Biotech & Nutrition's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Read More

Financials

Read More

Ratios

Read More

Shareholding

ShareholdersMAR 2026DEC 2025SEPT 2025JUN 2025MAR 2025
Promoters59.5359.5359.5359.5359.53
FII00000
DII0.200.200.200.200.20
Public40.2840.2840.2840.2840.28
Government00000

Read More

Technical Analysis

RSI

51.25

MACD

-0.08

50 DMA

25.56

200 DMA

28.42

Support and Resistance

TypeR3R2R1PPS1S2S3
Classic34.6530.1627.8325.6723.3421.1816.69
Fibonacci30.1628.4427.3825.6723.9522.8921.18
Camarilla26.7426.3325.9225.6725.1024.6924.28

Pivots Level: Classic

R3

+8.98

34.65

R2

+4.49

30.16

R1

+2.17

27.83

25.67
25.67
Pivot Point
LTP: 26.20

S1

-2.32

23.34

S2

-4.49

21.18

S3

-8.98

16.69

Moving Average

SMAEMA

Period

Value

  • 10-EMA

    25.86

  • 20-EMA

    25.98

  • 30-EMA

    25.98

  • 50-EMA

    26.05

  • 100-EMA

    26.77

  • 200-EMA

    28.55

Read More

Corporate Actions

Announcement DatePurposeActionEx Date
12 May 2026board-meetingsAccounts, Quarterly Results
11 Feb 2026board-meetingsQuarterly Results
07 Aug 2025agm
04 Sept 2024agm
27 Oct 2023egm
24 Aug 2023agm
05 Jul 2022agm
29 Jul 2021agm

Read More

Peer Comparison

Emmessar Biotech & Nutrition Ltd logo

Emmessar Biotech & Nutrition Ltd

Linde India Ltd logo

Linde India Ltd

SRF Ltd logo

SRF Ltd

Gujarat Fluorochemicals Ltd logo

Gujarat Fluorochemicals Ltd

Godrej Industries Ltd logo

Godrej Industries Ltd

Pidilite Industries Ltd logo

Pidilite Industries Ltd

Read More

Emmessar Biotech & Nutrition Ltd About

Emmessar Biotech & Nutrition The Company's primary line of business had been manufacturing and marketing of healthcare & nutritional products.

Industry

Chemicals

Founded

1992

Headquarters

CEO

MSR Ayyangar

Employees

Contact

Website icon

Website

http://www.ebnl.org

Email icon

Email

investors@ebnl.org

Phone icon

Phone

91-022-20870587

Location icon

Location

Plot No T-3/2 MIDC Area, P O Box No 39 Taloja, Raigad, Maharashtra, 410208

Read More

Emmessar Biotech & Nutrition Ltd Company History

YearHistory
2008
  • Emmessar Technologies Private Ltd became Emmessar Technologies Ltd
  • RESQ was launched as an unfailing solution for treating all types of burns from heat and radiation
  • Cute N Comely was launched as a premier topical application with protective and therapeutic properties for skin rejuvenation
2009
  • Frejomus tablets were launched to help mitigate joint pains that restrict movement for the middle and old aged people.
2010
  • Sepecer was launched as a reliable solution for neurological and physiological health for the middle ages and beyond.
2011
  • Psoribalm was launched to meet the long standing demand for a harmless and reliable treatment for Psoriasis.
2016
  • Over 30 newly developed products to meet a spectrum of healthcare needs were ready to be launched progressively from mid 2016 onwards.

Read More

Deals

Client NameDeal TypeOrder SideQTYAvg PriceDate
PRATIBHA DINESH SHAHbulkSell4333724.6627 Mar 2026
AIMS FINANCIAL VENTURESbulkBuy4500024.7227 Mar 2026
QUANTSEYE AI PRIVATE LIMITEDbulkSell2533329.2929 Jul 2025
PRATIBHA DINESH SHAHbulkBuy3818143.613 Dec 2024
SHRENIK DINESH SHAHbulkSell2600043.613 Dec 2024
AIMS FINANCIAL VENTURESbulkSell2599151.512 Nov 2024
SHRENIK DINESH SHAHbulkBuy2600051.512 Nov 2024
AIMS FINANCIAL VENTURESbulkBuy2598661.4216 Oct 2024
PRACHI PRAKASH RAKTATEbulkBuy3226463.4416 Oct 2024
PRACHI PRAKASH RAKTATEbulkSell458962.8516 Oct 2024

Read More

Emmessar Biotech & Nutrition Ltd News

Emmessar Biotech FY26 Results Published in Newspapers

Emmessar Biotech & Nutrition filed Regulation 30 compliance on May 13, 2026, confirming FY26 audited results published in Free Press Journal and Nav Shakti. FY26 net profit rose to ₹43.59 lacs.

13 May 2026

companies

Emmessar Biotech FY26 Net Profit Rises to ₹43.59 Lacs

Emmessar Biotech & Nutrition posted FY26 net profit of ₹43.59 lacs, up from ₹31.62 lacs in FY25. Total income stood at ₹240.66 lacs vs ₹261.96 lacs a year ago.

12 May 2026

companies

Emmessar Biotech Reports FY26 Audited Financial Results

Emmessar Biotech & Nutrition posted FY26 net profit of ₹43.59 lacs, up from ₹31.62 lacs in FY25. Total income stood at ₹240.66 lacs vs ₹261.96 lacs a year ago.

12 May 2026

companies

Emmessar Biotech Board Meet on May 12 for FY26 Results

Emmessar Biotech & Nutrition has scheduled a Board of Directors meeting on May 12, 2026, to consider and approve audited financial results for the year ended March 31, 2026.

05 May 2026

companies

Emmessar Biotech confirms non-applicability of SEBI

Emmessar Biotech & Nutrition Limited confirms it does not meet large corporate criteria under SEBI circular dated October 19, 2023, with nil outstanding borrowings as on March 31, 2025.

08 Apr 2026

companies

Read More